Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with adalimumab under the National Health Act 1953, section 85 for patients with moderate to severe hidradenitis suppurativa (HS).
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing adalimumab.
Treatment specifics
To be eligible for PBS-subsidised treatment with adalimumab, patients must be treated by a dermatologist.
Authority applications
Applying for initial or recommencement of treatment
Apply for initial or recommencement authority approval to prescribe PBS-subsidised adalimumab to treat moderate to severe HS in writing and either:
- upload through Health Professional Online Services (HPOS)
- post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- moderate to severe hidradenitis suppurativa initial authority application form
- relevant attachments.
Applying for continuing treatment
Apply for continuing authority approval to prescribe PBS-subsidised adalimumab to treat moderate to severe HS in writing and either:
- upload through HPOS
- post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- moderate to severe hidradenitis suppurativa continuing authority application form
- relevant attachments.
After we approve the first application for continuing treatment, subsequent continuing treatment with PBS-subsidised biosimilar brands of biological agents are Authority Required (Streamlined). They don’t need authority approval from us for listed quantity and repeats.
Further information
Call the PBS Complex Drugs Programs enquiry line for further information.